We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going ...

Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Vivek Ramaswamy, a former presidential candidate, is expected to announce his campaign for Ohio governor in 2026. In 2014 Ramaswamy co-founded Roivant Sciences, which buys or licenses promising ...

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports.

Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a ...